BRCA1 and ovarian cancer: In support of this notion, Stefansson et al. [131] showed that BRCA1 CpG island promoter hypermethylation-associated gene silencing can predict enhanced sensitivity to platinum-derived drugs in cancer cell lines and xenografted tumors, increase the time to relapse, and improve overall survival in ovarian cancer patients undergoing chemotherapy with cisplatin.